Patients with atopic dermatitis at higher risk for COVID-19 infection

Key clinical point: Patients with atopic dermatitis (AD) showed a significantly higher risk of contracting COVID-19 infection irrespective of comorbidities and other demographic factors.

Major finding: Patients with vs. without AD were more likely to have a diagnosis of COVID-19 (4.2% vs. 2.8%; P < .001) with AD remaining significantly associated with COVID-19 even after adjusting for demographic factors and comorbidities (odds ratio 1.29; P < .001).

Study details: Findings are from a case-control cohort, All of Us, including 11,752 patients with AD who were matched with 47,008 healthy controls.

Disclosures: This study did not report any funding. The authors declared no conflicts of interest.

Source: Fan R et al. JAAD Int. 2021 (Dec 27). Doi: 10.1016/j.jdin.2021.12.007.

Key clinical point: Patients with atopic dermatitis (AD) showed a significantly higher risk of contracting COVID-19 infection irrespective of comorbidities and other demographic factors.

Major finding: Patients with vs. without AD were more likely to have a diagnosis of COVID-19 (4.2% vs. 2.8%; P < .001) with AD remaining significantly associated with COVID-19 even after adjusting for demographic factors and comorbidities (odds ratio 1.29; P < .001).

Study details: Findings are from a case-control cohort, All of Us, including 11,752 patients with AD who were matched with 47,008 healthy controls.

Disclosures: This study did not report any funding. The authors declared no conflicts of interest.

Source: Fan R et al. JAAD Int. 2021 (Dec 27). Doi: 10.1016/j.jdin.2021.12.007.

Key clinical point: Patients with atopic dermatitis (AD) showed a significantly higher risk of contracting COVID-19 infection irrespective of comorbidities and other demographic factors.

Major finding: Patients with vs. without AD were more likely to have a diagnosis of COVID-19 (4.2% vs. 2.8%; P < .001) with AD remaining significantly associated with COVID-19 even after adjusting for demographic factors and comorbidities (odds ratio 1.29; P < .001).

Study details: Findings are from a case-control cohort, All of Us, including 11,752 patients with AD who were matched with 47,008 healthy controls.

Disclosures: This study did not report any funding. The authors declared no conflicts of interest.

Source: Fan R et al. JAAD Int. 2021 (Dec 27). Doi: 10.1016/j.jdin.2021.12.007.